Info
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Episodes & Posts
Episodes
Posts
18 FEB 2025 · Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “Prognostic clinical and biological markers for amyotrophic lateral sclerosis disease progression: validation and implications for clinical trial design and analysis”.
2 JAN 2025 · Dr. Jesse Crayle is a clinical neuromuscular fellow in the Department of Neurology at Washington University in St. Louis and Dr. Evadnie Rampersaud is a Principal Bioinformatics Research Scientist at St. Jude Children’s Research Hospital. They will be discussing their publication “Genetic Associations With an Amyotrophic Lateral Sclerosis Reversal Phenotype.”
4 DEC 2024 · Nuedexta is a combination of dextromethorphan and quinidine, and is FDA approved for treating “pseudobulbar affect” (a symptom complex where patients lose control of their laughing and crying). Here we summarize recent trials suggesting that Nuedexta might also help bulbar function (speech, swallowing and oral secretions). We also discuss important risks, monitoring, and insurance coverage.
4 NOV 2024 · Lions Mane is a mushroom that has neuroprotective, neurotrophic, antioxidant, and anti-inflammatory properties. Here we review what is known about its use in ALS models as well as patients living with the disease.
1 OCT 2024 · Insulin is a hormone most commonly used to lower blood sugar in people with diabetes. Here we talk about some theoretical ways it might help help people with ALS, as well as the lack of convincing case reports or trials and the risks.
5 SEP 2024 · Caffeine is a chemical most of us ingest every day. In addition to its stimulant properties, there are some theoretical ways it could help slow ALS progression. Here we discuss the contradictory pre-clinical models and the lack of a convincing relationship between caffeine intake and ALS progression in natural history studies.
13 AUG 2024 · Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. Here he discusses the recent publication “The Miami Framework for ALS and related neurodegenerative disorders: an integrated view of phenotype and biology”.
15 FEB 2024 · Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron diseases”.
3 JAN 2024 · Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure” and its role as a patient reported outcome measure for ALS.
15 NOV 2023 · Sodium chlorite is an experimental drug targeting macrophage activation. It exists in different formulations. An oral formulation has potentially deadly side effects. An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS. Here we review the interesting development of this product and where we expect that to go in the near future.
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
Information
| Author | CReATe Consortium |
| Organization | CReATe Consortium |
| Categories | Health & Fitness |
| Website | - |
| - |
Copyright 2025 - Spreaker Inc. an iHeartMedia Company
